It has been a very good year for the biopharmaceutical industry.
Given how 2017 began, that’s a remarkable statement. Despite the controversies, media attention, and congressional hearings, everything has turned up...
For those old drug re-pricing situations that reach headline and/or US congressional visibility, a tweak to the importation debate might offer a response.
It has been a very good year for the biopharmaceutical industry.
Given how 2017 began, that’s a remarkable statement. Despite the controversies, media attention, and congressional hearings, everything has turned up...
The billionaire investor said during a recent conference that brand drug manufacturers want to work with his Cost Plus Drug Co., but are afraid the PBMs will retaliate.
Canadian politicians must “move quickly” to introduce policies that will speed up access to medicines, such as by broadening criteria for the temporary reimbursement of medicines, the Canadian Chamber of Commerce says.
The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.